Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

What do we Really Know about Nanotoxicology of Silver Nanoparticles In vivo? New Aspects, Possible Mechanisms, and Perspectives

Full text
Author(s):
Duran, Nelson [1, 2, 3, 4] ; Favaro, Wagner J. [2, 3, 4] ; Scabra, Amcdca B. [1, 2, 4]
Total Authors: 3
Affiliation:
[1] Fed Univ ABC UFABC, Ctr Nat & Human Sci, Santo Andre, SP - Brazil
[2] Fed Univ ABC UFABC, Nanomed Res Unit NANOMED, Santo Andre, SP - Brazil
[3] Univ Estadual Campinas, UNICAMP, Inst Biol, Urogenital Carcinogenesis & Immunotherapy Lab, Dep, Campinas, SP - Brazil
[4] Univ Estadual Campinas, Inst Chem, Lab Nanostruct Synth & Biol Interact NanoBioss, Campinas, SP - Brazil
Total Affiliations: 4
Document type: Review article
Source: CURRENT NANOSCIENCE; v. 16, n. 3, p. 292-320, 2020.
Web of Science Citations: 0
Abstract

Actually, many discussions on the potential risks of silver nanoparticles (AgNPs) have been reported; however, unfortunately, very few considered the great differences between the nature of silver and sources of their syntheses. All data suggested that the effects on toxicity of AgNPs are related to the combination of the specific properties of AgNPs. In this context, this review presents and discusses the recent progress in the nanotoxicity of AgNPs, obtained by different biogenic synthetic protocols, in comparison with chemical synthetic methods, driving to the formation of nanoparticles with diverse structures, and size distributions. Biogenic syntheses of AgNPs using several biological sources and other chemical agents are presented and discussed. Toxicity in different animals is also presented and discussed. By considering the actual state of the art, it can be assumed that oral, intravenous and inhalation doses of AgNPs from 0.1 to 2 mg/Kg in mice and rats are considered a safe administration. In terms of ecotoxicity, it is more concerning since many of the in vivo assays showed a very low lethal dose, i.e., 50% (LD50). Therefore, we have to be very careful with the AgNPs residues in the environment. (AU)

FAPESP's process: 14/11154-1 - Development of graphene oxide hybrids as platform for the treatment of non-invasive bladder cancer: interactions of Bacillus Calmette-Gueri immunotherapy, metformin and RNA interference
Grantee:Joel Gonçalves de Souza
Support type: Scholarships in Brazil - Post-Doctorate
FAPESP's process: 18/08194-2 - Essential oil amended with metal nanoparticles functionalized with nitric oxide as a strategy to control of plant pathogens in the agriculture
Grantee:Amedea Barozzi Seabra
Support type: Regular Research Grants